Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Invested Capital (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Invested Capital data on record, last reported at -$99.0 million in Q3 2025.

  • For Q3 2025, Invested Capital fell 39.56% year-over-year to -$99.0 million; the TTM value through Sep 2025 reached -$99.0 million, down 39.56%, while the annual FY2024 figure was -$84.9 million, 50.06% down from the prior year.
  • Invested Capital reached -$99.0 million in Q3 2025 per NWBO's latest filing, down from -$91.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at -$11.3 million in Q1 2021 and bottomed at -$112.2 million in Q1 2022.
  • Average Invested Capital over 5 years is -$60.3 million, with a median of -$61.2 million recorded in 2023.
  • Peak YoY movement for Invested Capital: soared 95.15% in 2021, then tumbled 890.18% in 2022.
  • A 5-year view of Invested Capital shows it stood at -$17.2 million in 2021, then crashed by 176.31% to -$47.5 million in 2022, then fell by 19.02% to -$56.6 million in 2023, then crashed by 50.06% to -$84.9 million in 2024, then fell by 16.58% to -$99.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were -$99.0 million in Q3 2025, -$91.3 million in Q2 2025, and -$98.4 million in Q1 2025.